Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Rani Therapeutics : Announces Appointment of Eric Groen as General Counsel

09/09/2021 | 08:02am EST

SAN JOSE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics, today announced the appointment of Eric Groen as General Counsel. Mr. Groen has more than 25 years of experience managing legal matters in corporate and private practice.

“Eric is an accomplished executive whose legal expertise and business acumen have enabled him to handle complex legal matters across the breadth of biopharmaceutical operations, from R&D to manufacturing to commercial, with particular expertise in leading biopharmaceutical transactions. We look forward to his contributions as we continue to progress the RaniPill™ capsule technology and advance our clinical pipeline,” said Talat Imran, Rani’s Chief Executive Officer. “I am thrilled to welcome Eric to our team as we pursue our goal of making oral biologics a reality so that we may be able to help millions of people suffering from chronic diseases.”

Mr. Groen has extensive legal experience in the biopharmaceutical industry. Prior to joining Rani, Mr. Groen served in various domestic and international roles of increasing responsibility over nearly 20 years at Amgen, including leading the legal teams responsible for business development transactions, operations and manufacturing, and clinical trials. Most recently, he served as regional general counsel to Amgen’s commercial business in Canada, Latin America, Middle East and Africa. Mr. Groen began his career in private practice at the law firm of TroyGould, where he practiced in the areas of corporate finance, securities compliance, corporate governance, and mergers and acquisitions. Mr. Groen holds a J.D. from Harvard Law School and a B.A. in Political Science from UC Santa Barbara.

About Rani Therapeutics

Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed the RaniPill™ capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection of biologics with oral dosing. Rani has conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Rani’s advancement of its RaniPill™ capsule technology. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “may,” “look forward,” “progress,” “advance” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Rani’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Media Relations


Investor Relations


Primary Logo

Source: Rani Therapeutics, LLC

2021 GlobeNewswire, Inc., source Press Releases

11/16RANI THERAPEUTICS : Reports Third Quarter 2021 Financial Results, Provides Corporate Updat..
11/16RANI THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Con..
11/15Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Upda..
11/15Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Upda..
11/12RANI THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)
11/12Rani Therapeutics Appoints Lyn Baranowski to Board of Directors
11/12Rani Therapeutics Holdings, Inc. Appoints Lyn Baranowski to Board of Directors
11/10Rani Therapeutics to Participate in a Fireside Chat at the Stifel 2021 Virtual Healthca..
09/29RANI THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhi..
09/23Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
More news
Analyst Recommendations on RANI THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 2,70 M - -
Net income 2021 -53,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -20,5x
Yield 2021 -
Capitalization 463 M 463 M -
Capi. / Sales 2021 172x
Capi. / Sales 2022 926x
Nbr of Employees 91
Free-Float 9,27%
Duration : Period :
Rani Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RANI THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 23,50 $
Average target price 28,40 $
Spread / Average Target 20,9%
EPS Revisions
Managers and Directors
Talat Imran Chief Executive Officer & Director
Svai S. Sanford Chief Financial Officer
Mir A. Imran Executive Chairman
Mir Hashim Chief Scientific Officer
Dennis Arthur Ausiello Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888